Neoadjuvant Chemotherapy Does Not Improve Survival in cT2N0M0 Gastric Adenocarcinoma Patients: A Multicenter Propensity Score Analysis.
Francesco AbborettiCéline LambertMarkus SchäferBruno PereiraBertrand Le RoyDiane MègeGuillaume PiessenJohan GagnièreCaroline GronnierStyliani Mantziarinull nullnull nullPublished in: Annals of surgical oncology (2024)
Patients with cT2N0M0 gastric adenocarcinoma did not present a survival or recurrence benefit if treated with perioperative chemotherapy followed by surgery as opposed to surgery alone.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- minimally invasive
- squamous cell carcinoma
- coronary artery bypass
- rectal cancer
- free survival
- newly diagnosed
- computed tomography
- end stage renal disease
- image quality
- dual energy
- ejection fraction
- contrast enhanced
- radiation therapy
- lymph node
- sentinel lymph node
- magnetic resonance imaging
- surgical site infection
- prognostic factors
- patients undergoing
- clinical trial
- early stage
- cross sectional
- acute kidney injury
- atrial fibrillation